摘要
哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)是一种丝/苏氨酸蛋白激酶,在细胞生长、增殖、分化、细胞周期调控等多个方面起到重要作用。近年来发现mTOR相关的信号通路复杂且涉及面广泛,其中多个元素的调控异常都与肿瘤的发生密切相关。mTOR抑制剂能够抑制由于该信号通路异常引起的癌基因的转化、肿瘤的生长和肿瘤血管生成。到目前为止,4种mTOR抑制剂被有效地应用于临床,有的已进入Ⅱ、Ⅲ期临床试验。因此,对mTOR信号通路的深入研究对肿瘤的靶向性治疗具有重要意义。
Mammalian target of rapamycin （mTOR） is a serine/threonine protein kinase that is centrally involved in the control of cell growth, proliferation, differentiation and cell cycle regulation. Recent studies have found that the mTOR pathway is complicated and the dysregulation of mTOR pathway is recognized to be associated with lots of tumors. Several inhibitors of mTOR could inhibit oncogene transformation, growth and angiogenesis of tumors. So far, four inhibitors of mTOR have been tested in clinical trials, and some have been accessed to phase Ⅱ or Ⅲtrial. Therefore, in this review, we discuss the regulators that govern mTOR pathway activity, and highlight clinical results obtained with the first generation of mTOR inhibitors to reach the oncology clinics.
出处
《西安交通大学学报（医学版）》
CAS
CSCD
北大核心
2010年第1期1-9,共9页
Journal of Xi’an Jiaotong University（Medical Sciences）
基金
国家自然科学基金资助项目(No.30571951)
国家自然科学杰出青年基金项目(No.30725043)
教育部985-2期工程(肿瘤干细胞研究)~~
